Merck's women's health spinout snags mid-stage candidate for preterm birth; Keytruda nails down TNBC approval after March CRL
Nearly two months after spinning out from Merck, women’s health business Organon has struck its first half-billion-dollar deal.
Organon $OGN has
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
